Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Minerals Announces MOU with Granada Gold on Milling Assessment (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more

Recent & Breaking News (NDAQ:BCRX)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 6, 2025

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

GlobeNewswire February 24, 2025

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

GlobeNewswire February 24, 2025

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire February 19, 2025

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

GlobeNewswire February 12, 2025

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

GlobeNewswire February 10, 2025

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

GlobeNewswire February 10, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 4, 2025

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

GlobeNewswire January 10, 2025

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 6, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 4, 2024

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

GlobeNewswire November 18, 2024

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire November 6, 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 5, 2024

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 4, 2024

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

GlobeNewswire October 24, 2024

BioCryst to Report Third Quarter 2024 Financial Results on November 4

GlobeNewswire October 21, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

GlobeNewswire October 14, 2024

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

GlobeNewswire October 10, 2024